On Friday, Shares of Williams Companies, Inc. (NYSE:WMB), gained 3.38% to $57.12.
The Williams Companies, declared that Sarah Miller has been named general counsel of the company, effective June 20, 2015. Williams’ board of directors has confirmed Miller’s role. She will report directly to Williams President and Chief Executive Officer Alan Armstrong.
Miller will lead Williams’ legal team, succeeding Craig Rainey who has stepped down. Miller, who formerly served as vice president, corporate secretary and assistant general counsel for the company’s corporate secretary team, was designated to the interim general counsel position in March 2015.
Miller joined Williams in 2000 and has served in a variety of legal leadership roles. In addition to serving as corporate secretary and assistant general counsel, she has also served as senior counsel for the company’s midstream business, and as senior attorney for the legal department’s business development team. Preceding to joining Williams, Miller was a litigation associate at Crowe & Dunlevy.
The Williams Companies, Inc. operates as an energy infrastructure company primarily in the United States. The company operates in three segments: Williams Partners, Access Midstream, and Williams NGL & Petchem Services.
Shares of DURECT Corporation (NASDAQ:DRRX), inclined 1.21% to $2.50, during its last trading session.
DURECT Corporation, declared that, based on feedback from the FDA, it plans to conduct a new POSIDUR™ (SABER®-Bupivacaine) Phase 3 clinical trial comprising of about 300 patients undergoing laparoscopic cholecystectomy (gallbladder removal) surgery. DURECT anticipates starting the trial in the fall of 2015 and anticipates that it will take about one year to complete enrollment.
“With the FDA’s guidance in hand, we now have a clear path forward for POSIDUR,” stated James E. Brown, President and CEO of DURECT. “We believe that the data from this additional clinical trial will be supportive of the data we have seen in our other pivotal trials in hernia repair and shoulder surgery, and that these three pivotal trials will support a robust NDA resubmission, for which there would be a 6 month review per PDUFA guidelines. We have previous clinical trial experience with laparoscopic cholecystectomy, which is one of the most common general surgeries performed in the U.S. each year. We believe this is an excellent surgical model and that our overall clinical program for POSIDUR will support a broad label.”
DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceuticals products based on its proprietary drug formulations and delivery platform technologies in the United States, Europe, Japan, and internationally.
Finally, Cardinal Health, Inc. (NYSE:CAH), ended its last trade with -0.74% loss, and closed at $85.64.
A series of new clinical studies demonstrates the essential role that patient-stated outcomes (PRO) analysis can play in advancing patient-centered care. These studies also illustrate the feasibility of leveraging user-friendly technology solutions to collect PRO data in real-time, at the point of care.
In a recent Q&A blog post on Cardinal Health’s online thought leadership site, Essential Insights, Dr. Bruce Feinberg, vice president and chief medical officer of Cardinal Health Specialty Solutions, shares his insights on how PRO analysis can assist improve the quality of care while driving down costs. Dr. Feinberg shared this research at the 2015 International Society of Pharmacoeconomic and Outcomes Research (ISPOR) 20th Annual International Meeting.
“The research we highlighted at ISPOR 2015 reinforces a simple truth – if we want to find ways to improve the quality of life and reduce costs of caring for patients with complex diseases, we need to start by talking to patients themselves,” says Dr. Feinberg. “Patient stated outcomes data can assist physicians determine the most appropriate course of treatment – and address not only the disease, but also patient’s needs.”
Cardinal Health, Inc., a healthcare services company, provides pharmaceutical and medical products and services in the United States and internationally. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, over-the-counter healthcare, specialty pharmaceutical, and consumer products to retailers, counting chain and independent drug stores and pharmacy departments of supermarkets and mass merchandisers; hospitals; and other healthcare providers.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
